Imara reduced to six employees as the biotech, once again preclinical, explores its options

Imara will employ just six people by the end of this quarter as 83% of the staff has been shown the exit following the biotech’s Phase IIb flops earlier this month.

The company will likely have to find a buyer or shut down. Imara’s main goal and likely only priority at this point — after ending work on its sickle cell disease and beta-thalassemia drug — is undergoing a “comprehensive assessment of its strategic options to maximize shareholder value.”

Read the source article at endpts.com
2022-04-18 15:32:33